Skip to main content

Table 1 Patient demographics and disease characteristics

From: Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer

Characteristic

Lapatinib + vinorelbine (N=44)*

Age, years

 

 Median (range)

56.0 (29–82)

Race, n (%)

 

 Caucasian/White

32 (73)

 African American/African heritage

12 (27)

ECOG status at baseline, n (%)

 

 0

25 (57)

 1

19 (43)

HER2 status, n (%)

 

 FISH+ (with or without IHC+)

27 (61)

 IHC 3+ (only)

29 (66)

ER/PgR status, n (%)

 

 ER+ and/or PgR+

23 (52)

 ER- and PgR-

21 (48)

Stage at initial diagnosis, n (%)

 

 0

1 (2)

 I

3 (7)

 II

15 (34)

 III

14 (32)

 IV

11 (25)

Number of prior metastatic chemotherapeutic regimen (s), n (%)

 

 0

23 (52)

 1

21 (48)

Median time since first diagnosis, months (range)

28.8 (1–126)

Prior anti-cancer therapy, n (%)

43 (98)

 Chemotherapy

35 (80)

 Immunotherapy

1 (2)

 Hormonal therapy

18 (41)

 Biologic therapy

35 (80)

 Surgery

43 (98)

 Radiotherapy

23 (52)

  1. *All patients were female. ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, Human epidermal growth factor receptor 2; IHC, immunochemistry; PgR, progesterone receptor.